Background: Coronavirus Disease 2019 (covid-19) is a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). People who are infected with SARS-CoV-2 or are vaccinated with covid-19 vaccines are supposed to develop immunoglobulins and these immune responses in human body will determine the efficacy of the vaccines as well as help to discover new therapeutic options. Methods: A cross-sectional study conducted between April to June, 2021, assessing serum antibody titer from participants who had taken the first dose of covishieldTM vaccine (naïve as well as prior covid-19 infected individuals). Antibody testing was carried out with Roche Elecsys Anti-SARS-CoV-2 S electrochemiluminescence immunoassay on Roche Cobas e 601 module. Twenty-eight of these participants had follow up repeat antibody test after second dose of vaccine. Results: A total of 122 participants with the first dose of CovishieldTM vaccine were all tested seropositive, antibody titer ranging from minimum of 2.95 U/mL to maximum 2500 U/mL. Average antibody titer was 308.9 U/mL for naive cohort and 1604 U/mL for prior covid-19 infection. In twenty-eight participants who had antibody titer measured after 1 month of second dose, average titer was 1459.7 U/mL for naïve cohort and 1803.4 U/mL for prior covid-19 infected individuals, which was statistically significant compared to antibody response after the first dose. Conclusions: Antibody responses against SARS-CoV-2 following immunization was 100%, with significant development after second dose in naïve population while robust immune response was present after first dose in prior SARS-CoV-2 infected individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.